Dermira

Biotech

Lilly’s $1B bet yields 'compelling' data on Dupixent rival

Analysts at Jefferies called the data compelling, although a hoped-for point of differentiation over the blockbuster incumbent has weakened.
Nick Paul Taylor Mar 28, 2022 7:40am

Evommune snags $83M for "Tylenol for itch," three other programs

Sep 9, 2021 7:30am

Aslan hires Kobayashi to add IL-13 clinical trial expertise 

Aug 3, 2020 8:56am

Pfizer’s Dupixent rival makes the grade in phase 3—again

Mar 18, 2020 8:44pm

Lilly bags late-phase Dupixent rival in $1.1B Dermira buyout

Jan 10, 2020 8:20am

Pfizer's JAK inhibitor hits the mark in another eczema trial

Sep 27, 2019 11:11am